Valneva SE

ENXTPA:VLA 株式レポート

時価総額:€448.9m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

Valneva 過去の業績

過去 基準チェック /06

Valnevaの収益は年間平均-22.8%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間11.8% 22.6%割合で 増加しています。

主要情報

-22.8%

収益成長率

-17.3%

EPS成長率

Biotechs 業界の成長30.8%
収益成長率22.6%
株主資本利益率-12.9%
ネット・マージン-15.9%
次回の業績アップデート13 Aug 2024

最近の業績更新

Recent updates

Valneva SE (EPA:VLA) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 10
Valneva SE (EPA:VLA) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Valneva SE's (EPA:VLA) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Apr 05
Valneva SE's (EPA:VLA) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Analyst Forecasts Just Became More Bearish On Valneva SE (EPA:VLA)

Mar 27
Analyst Forecasts Just Became More Bearish On Valneva SE (EPA:VLA)

Is Valneva (EPA:VLA) Weighed On By Its Debt Load?

Mar 15
Is Valneva (EPA:VLA) Weighed On By Its Debt Load?

News Flash: Analysts Just Made A Captivating Upgrade To Their Valneva SE (EPA:VLA) Forecasts

Jan 06
News Flash: Analysts Just Made A Captivating Upgrade To Their Valneva SE (EPA:VLA) Forecasts

Valneva (EPA:VLA) Has Debt But No Earnings; Should You Worry?

Dec 13
Valneva (EPA:VLA) Has Debt But No Earnings; Should You Worry?

Does Valneva (EPA:VLA) Have A Healthy Balance Sheet?

Aug 10
Does Valneva (EPA:VLA) Have A Healthy Balance Sheet?

Valneva SE's (EPA:VLA) Business And Shares Still Trailing The Industry

May 12
Valneva SE's (EPA:VLA) Business And Shares Still Trailing The Industry

Valneva (EPA:VLA) Takes On Some Risk With Its Use Of Debt

Jan 30
Valneva (EPA:VLA) Takes On Some Risk With Its Use Of Debt

Is Valneva (EPA:VLA) Using Debt Sensibly?

Sep 18
Is Valneva (EPA:VLA) Using Debt Sensibly?

Industry Analysts Just Upgraded Their Valneva SE (EPA:VLA) Revenue Forecasts By 55%

Aug 13
Industry Analysts Just Upgraded Their Valneva SE (EPA:VLA) Revenue Forecasts By 55%

収支内訳

Valneva の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

ENXTPA:VLA 収益、費用、利益 ( )EUR Millions
日付収益収益G+A経費研究開発費
31 Mar 24153-241010
31 Dec 23154-101970
30 Sep 23223-113900
30 Jun 23431-777-26
31 Mar 23373-135690
31 Dec 22361-143580
30 Sep 2243973610
30 Jun 22304-1596552
31 Mar 22347-72640
31 Dec 21348-73710
30 Sep 21121-248600
30 Jun 21110-125560
31 Mar 2198-91500
31 Dec 20110-64460
30 Sep 20104-62460
30 Jun 20120-25430
31 Mar 20127-8440
31 Dec 19126-2430
30 Sep 191164400
30 Jun 191091390
31 Mar 191167380
31 Dec 181133380
30 Sep 18107-7380
30 Jun 18110-7380
31 Mar 18108-8350
31 Dec 17105-11330
30 Sep 17103-11330
30 Jun 17100-14320
31 Mar 17102-46320
31 Dec 1698-49310
30 Sep 1693-63290
30 Jun 1696-61280
31 Mar 1689-35270
31 Dec 1583-21240
30 Sep 1574-16200
30 Jun 1565-13170
31 Mar 1555-9150
31 Dec 1442-26140
30 Sep 1441-21130
30 Jun 1443-28170
31 Mar 1441-29170
31 Dec 1336-24150
30 Sep 1326-22140

質の高い収益: VLAは現在利益が出ていません。

利益率の向上: VLAは現在利益が出ていません。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: VLAは利益が出ておらず、過去 5 年間で損失は年間22.8%の割合で増加しています。

成長の加速: VLAの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: VLAは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 3% ) と比較することは困難です。


株主資本利益率

高いROE: VLAは現在利益が出ていないため、自己資本利益率 ( -12.89% ) はマイナスです。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘